Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT06001788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06001788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 22, 2024
Completion date
August 31, 2027
Enrollment
171 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute myeloid leukemia, aml, aml with mutated npm1, hematologic malignancy, kmt2ar, leukemia, leukemia, myeloid, leukemia, myeloid, acute, mll rearrangement, neoplasms by histologic type, npm1 mutation